# Beam Therapeutics (BEAM) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/BEAM
## Company Profile
- Ticker: BEAM
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 26.71 USD
- Market cap: 2979382037.44 USD
- Last updated: 2026-08-12
## Business Overview
### Base Editing
Beam Therapeutics develops precision genetic medicines using base editing, which can change individual DNA bases without creating double-strand breaks. The company integrates editing, delivery and manufacturing capabilities.
### BEAM-302
BEAM-302 is an in vivo liver-editing candidate for alpha-1 antitrypsin deficiency and is moving into a global pivotal cohort.
### BEAM-301
BEAM-301 is an in vivo base-editing therapy for glycogen storage disease type Ia that has entered clinical evaluation.
### BEAM-304
BEAM-304 is a liver-directed base-editing candidate for phenylketonuria and is preparing for an IND submission.
### Sickle Cell Disease
Risto-cel is an ex vivo base-edited hematopoietic stem-cell therapy for sickle cell disease and is approaching a potential U.S. regulatory submission.
## Why The Stock Is Moving

As of Aug 12, 2026, BEAM closed down 0.52% at $26.71. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of a global pivotal cohort for BEAM-302 in the second half of 2026.
- IND submission for BEAM-304 during 2026.
- Additional BEAM-301 clinical data during 2026.
- BLA submission for risto-cel as early as year-end 2026.

## Drug Assets

- BEAM-302

## Recent News
- 2026-08-04 11:00 EST — [Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)](https://biopharmsignal.com/news/BEAM/beam-therapeutics-reports-second-quarter-2026-financial-results-and-announces-fi-f3a9cb51) — Source: Beam Therapeutics
- 2026-07-23 11:00 EST — [Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026](https://biopharmsignal.com/news/BEAM/beam-therapeutics-to-present-updated-data-from-phase-1-2-trial-of-beam-302-in-al-9a5bdf4f) — Source: Beam Therapeutics
- 2026-06-18 11:00 EST — [Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration](https://biopharmsignal.com/news/BEAM/beam-therapeutics-announces-clearance-of-investigational-new-drug-application-fo-e796a8e2) — Source: Beam Therapeutics
- 2026-05-18 20:00 EST — [Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference](https://biopharmsignal.com/news/BEAM/beam-therapeutics-presents-recently-reported-topline-clinical-data-for-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-american-thoracic-society-ats-2026-international-conference) — Source: Beam Therapeutics
- 2026-05-13 11:00 EST — [Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference](https://biopharmsignal.com/news/BEAM/beam-therapeutics-to-present-at-2026-rbc-capital-markets-global-healthcare-conference) — Source: Beam Therapeutics